Your browser doesn't support javascript.
loading
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Kudo, Masatoshi; Hatano, Etsuro; Ohkawa, Shinichi; Fujii, Hirofumi; Masumoto, Akihide; Furuse, Junji; Wada, Yoshiyuki; Ishii, Hiroshi; Obi, Shuntaro; Kaneko, Shuichi; Kawazoe, Seiji; Yokosuka, Osamu; Ikeda, Masafumi; Ukai, Katsuaki; Morita, Sojiro; Tsuji, Akihito; Kudo, Toshihiro; Shimada, Mitsuo; Osaki, Yukio; Tateishi, Ryosuke; Sugiyama, Gen; Abada, Paolo Benjamin; Yang, Ling; Okusaka, Takuji; Zhu, Andrew Xiuxuan.
Afiliación
  • Kudo M; Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan. m-kudo@med.kinki.ac.jp.
  • Hatano E; Kyoto University Hospital, Kyoto, Japan.
  • Ohkawa S; Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
  • Fujii H; Jichi Medical University, Shimotsuke, Tochigi, Japan.
  • Masumoto A; Aso Iizuka Hospital, Fukuoka, Japan.
  • Furuse J; Kyorin University School of Medicine Hospital, Tokyo, Japan.
  • Wada Y; National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
  • Ishii H; The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Obi S; Kyoundo Hospital, Sasaki Institute, Tokyo, Japan.
  • Kaneko S; Kanazawa University Hospital, Ishikawa, Japan.
  • Kawazoe S; Saga-Ken Medical Centre Koseikan, Saga, Japan.
  • Yokosuka O; Chiba University Hospital, Chiba, Japan.
  • Ikeda M; National Cancer Center Hospital East, Chiba, Japan.
  • Ukai K; Sendai Medical Center, Sendai, Miyagi, Japan.
  • Morita S; Kochi Health Sciences Center, Kochi, Japan.
  • Tsuji A; Kagawa University Hospital, Takamatsu, Kagawa, Japan.
  • Kudo T; Osaka University Hospital, Osaka, Japan.
  • Shimada M; Tokushima University Hospital, Tokushima, Japan.
  • Osaki Y; Osaka Red Cross Hospital, Osaka, Japan.
  • Tateishi R; The University of Tokyo Hospital, Tokyo, Japan.
  • Sugiyama G; Kurume University Medical Center, Fukuoka, Japan.
  • Abada PB; Eli Lilly and Company, Indianapolis, IN, USA.
  • Yang L; Eli Lilly and Company, Bridgewater, NJ, USA.
  • Okusaka T; National Cancer Center Hospital, Tokyo, Japan.
  • Zhu AX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
J Gastroenterol ; 52(4): 494-503, 2017 Apr.
Article en En | MEDLINE | ID: mdl-27549242
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Aromoterapia Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: J Gastroenterol Año: 2017 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Métodos Terapéuticos y Terapias MTCI: Terapias_biologicas / Aromoterapia Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma Hepatocelular / Neoplasias Hepáticas / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: J Gastroenterol Año: 2017 Tipo del documento: Article País de afiliación: Japón